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Summary 
Neurodegenerative disorders are devastating brain diseases whose importance for the 
ageing population is steadily increasing. Huntington's disease (HD) is the most common 
known autosomal dominantly inherited neurodegenerative disorder caused by an expanded 
polyglutamine tract in the protein called huntingtin. Its characteristic neuropathological 
changes mainly affect the striatum. Despite continuous research efforts, the exact 
pathomechanism causing neurodegeneration is not fully known, and there is no specific 
neuroprotective therapy for Huntington’s disease or any other neurodegenerative disease so 
far. 
We investigated some aspects of two pathogenic hallmarks thought to be important in 
neurodegenerative diseases: disrupted axonal transport and mitochondrial dysfunction. 
Dynein is a motor protein responsible for intracellular transport of cargoes toward the minus-
end of microtubules and mediates retrograde axonal transport in neurons. Cramping mice 
bearing a point mutation in the dynein cytoplasmic heavy chain gene exhibit disturbed dynein 
function and develop characteristic phenotype including hind limb clasping, twisting the body 
and progressive loss of muscle tone. This phenotype is partially explained by early-onset 
sensory neuropathy. Substantial body of evidence suggest the involvement of mitochondrial 
dysfunction in neurodegeneration, and increased mitochondrial mass is observed in many of 
these diseases. This mitochondrial proliferation is suggested to be a compensatory 
mechanism, however the underlying processes are not fully known. Peroxisome proliferator-
activated receptor (PPAR) gamma coactivator 1 alpha (PGC-1α) is a transcriptional 
coactivator considered as master regulator of mitochondrial biogenesis and metabolism, 
moreover loss of its function was proposed as a key factor during neurodegeneration. 
We showed that Cramping mice carrying a dynein point mutation have striatal 
involvement which may be responsible for their behavioural abnormalities, such as 
hyperactivity, progressive motor incoordination and early muscle weakness. We confirmed 
the selective down-regulation of D1 dopamine receptors expression, striatal atrophy, 
accompanied with enlargement of lateral ventricles, decreased binding to either D1 or D2 
dopamine receptors and prominent astrocytosis in the striatum of Cramping mice. All these 
findings support the in vivo requirement of cytoplasmic dynein in the function of the striatum, 
and highlight the importance of the dynein motor and axonal transport disruption in the 
pathogenesis of striatal diseases, notably Huntington's disease.  
Others from our workgroup described systemic mitochondrial dysfunction (Eschbach et 
al., 2013) and compensatory mitochondrial proliferation accompanied by PGC-1α activation 
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in Cramping mice. We demonstrated that the genetic ablation of full length PGC-1α (FL- 
PGC-1α) in Cramping mice completely abolished the previously observed increases in 
mitochondrial DNA levels in muscles and reverted the mitochondrial phenotype. Moreover 
FL-PGC-1α ablation significantly worsened the overall and neurological phenotype of 
Cramping mice. Thus, FL-PGC-1α is required for the compensatory maintenance of 
mitochondrial function in vivo. This observation contributes to a better understanding of the 
underlying mechanisms in mitochondrial dysfunction related to disease. 
Further, we tested the effects of L-carnitine (LC) administration in the N171-82Q 
transgenic mouse model of HD. LC is an antioxidant nutrient also enhancing mitochondrial 
function. We demonstrated that L-carnitine administration in higher dose significantly 
extended the survival and ameliorated the motor symptoms of the N171-82Q transgenic HD 
mice. Moreover it preserved striatal neuron count and decreased the number of intranuclear 
huntingtin aggregates. Thus, our data suggest that L-carnitine is neuroprotective and may 
possibly be beneficial in the treatment of Huntington's disease. 
In all, our data highlight the role of the molecular motor dynein and mitochondrial 
dysfunction in neurodegeneration, notably in Huntington's disease. These findings contribute 
to better understanding of the pathomechanism of neurodegenerative diseases and offer 
potential therapeutic ways. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
7 
I. Introduction 
Neurodegenerative disorders are devastating diseases characterized by progressive, 
selective loss of specific neuronal systems. Besides the vulnerable neurons, the damage 
develops also in neighbouring non-neuronal supporting cells, and in multiple cell types in the 
periphery (Ilieva et al., 2009). Despite recent and continuous research efforts the exact 
pathomechanism which causes neuronal dysfunction and cell death still remains unknown in 
the most common sporadic or familial neurodegenerative diseases such as Alzheimer’s 
disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), and in the 
inherited forms such as Huntington’s disease (HD), where the disease causing gene and its 
protein product is known. Despite the heterogeneity of neurodegenerative diseases, there are 
several common factors well documented for their importance in pathogenesis. Two of these 
factors, disrupted axonal transport and mitochondrial dysfunction, were investigated during 
this PhD work, with special focus on Huntington's disease.  
 
I.1. Huntington's disease 
Huntington’s disease (HD) is the most common known autosomal dominantly inherited 
neurodegenerative disorder. Clinically it is characterized by motor dysfunction, cognitive and 
behavioural impairment and psychiatric disturbances, typically starting in mid-life and 
progressing relentlessly to death after a course of 10-25 years (Walker, 2007). The motor 
abnormalities of HD derive from dysfunction of brain regions involved in involuntary 
movement control, in particular the striatum, leading to uncontrollable dance-like movements 
(‘‘chorea’’) as a clinical hallmark. Progressive gait impairment, brady-, and hypokinesia also 
develop.  
HD is caused by expansion of a cytosine-adenine-guanine (CAG) trinucleotide repeat in 
the protein coding region of the IT15 gene encoding an elongated polyglutamine tract in the 
huntingtin (HTT) protein (The Huntington's Disease Collaborative Research Group, 1993). 
The number of CAG repeats in the gene determines HD phenotype. Normal alleles also 
contain CAG repeats, with 35 or less being non-pathogenic. Incomplete penetrance is 
observed with 36–39 repeats. Over 40 repeats, the disease is fully penetrant. The length of 
CAG repeats expansion has been shown to account for about 60% of the variation in age-at-
onset, with the remainder represented by modifying genes and environmental factors (Gusella 
and Macdonald, 2009, Weydt et al., 2009). Neuropathological hallmark of HD is the loss of 
gamma-aminobutyric acidergic medium-sized spiny neurons (MSNs) in the striatum, neurons 
in the deeper layers of the cerebral cortex are also affected (Walker, 2007). The N-terminal 
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fragments of mutant HTT accumulate in the nuclei of the affected neurons and form 
intranuclear aggregates (DiFiglia et al., 1997, Gutekunst et al., 1999). 
A great advantage for investigating the pathomechanism of HD or testing potential 
protective compounds is the existence of animal models of the disease. Transgenic mice 
expressing the N-terminal fragment of HTT with 82 CAG repeat, develop a progressive 
neurological disorder (Schilling et al., 1999). These mice (N171-82Q) fail to gain weight, 
exhibit an irregular, uncoordinated gait, hypokinesis, tremor and frequent hind limb clasping. 
In the open field they show decreased spontaneous locomotor activity and reduced 
explorative behaviour (Klivényi et al., 2006). The animals have shortened lifespan, as they die 
at an average age of 110-130 days. The brain of these mice is slightly smaller, but grossly 
normal, and exhibits striatal atrophy and neuronal intranuclear inclusions that are 
immunopositive for huntingtin and ubiquitin (Schilling et al., 1999). The N171-82Q mouse 
strain has the advantage of a relatively fast disease progression which provides a good 
practical use of testing potentially neuroprotective compounds compared with other 
transgenic (Hodgson et al., 1999) or knock-in (Lin et al., 2001; Menalled et al., 2003) HD 
mouse models. Still this strain displays slighter phenotype than R6/2 transgenic mice 
(Mangiarini et al., 1996), which enables the tested compound to exert its supposed beneficial 
effects and facilitates the detection of potential differences in the onset of symptoms. 
 
I.2. Axonal transport and the molecular motor dynein 
Axonal transport is a bidirectional process through which materials and signals are 
exchanged between the neuronal cell body and the synapse. Neurons are among the largest 
cells in humans and have extensive processes with large distances separating neuronal cell 
bodies from axons and synapses which makes them uniquely dependent on axonal transport 
(Eschbach and Dupuis, 2011; Schiavo et al., 2013; Chevalier-Larsen and Holzbaur, 2006; 
Morfini et al., 2009). Protein synthesis occurs in the cell body, vesicles and materials are 
anterogradely transported to the synapses. On the other hand cell body is the site for 
degradation of misfolded or aggregated proteins, retrograde transport is required for return of 
degradation products. Further, communication between the cell periphery and the cell center 
via transport of signalling complexes and neurotrophic factors is also crucial for neuronal 
maintenance and survival. Axonal transport is mediated primarily by microtubule-based 
molecular motors, large enzymes that use the energy of ATP hydrolysis to generate 
movement. Members of the kinesin superfamily are most, but not all, responsible for 
anterograde transport, while retrograde axonal transport is mainly mediated by the 
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cytoplasmic dynein (Goldstein and Yang, 2000). 
Cytoplasmic dynein is ubiquitously expressed, and is indispensable for the normal 
development. It is a large motor protein complex composed by different subunits such as the 
heavy chain, intermediate chains, light-intermediate chains and light chains (Pfister et al., 
2006). At the core of the molecule lies a homodimer of heavy chains forming the sites of ATP 
binding and microtubule binding (Gee et al., 1997; Pfister et al., 2005; Gennerich et al., 
2007). At the base of the motor are a number of intermediate, light-intermediate and light 
chains which are thought to function by maintaining the stability of the complex and cargo 
attachment (Banks and Fisher, 2008). Dynein functions in association with a multi-protein 
regulatory complex called dynactin (Schafer et al., 1994; Karki and Holzbaur, 1995) which 
participates in cargo binding but binds also directly to microtubules probably to increase the 
efficiency of dynein mediated motility (King and Schroer, 2000). As the motor complex 
dynein/dynactin is mainly responsible for the retrograde transport, one of the most important 
roles might be the removal of aggregation-prone proteins from the cell periphery to the place 
of degradation (Rubinsztein et al., 2005). Of note, besides the role in the retrograde axonal 
transport, dynein is involved in other basic cellular functions, such as endoplasmic reticulum 
and Golgi trafficking, mitosis, autophagy and is required for normal development. 
Loss of dynein/dynactin function is considered an important factor in the pathogenesis 
of neurodegenerative diseases (Eschbach and Dupuis, 2011; Schiavo et al., 2013; Chevalier-
Larsen and Holzbaur, 2006; Levy and Holzbaur, 2006). Impairment of retrograde axonal 
transport appears to be one of the earliest pathogenic changes during neurodegeneration 
(Morfini et al., 2009), and transgenic inhibition of retrograde axonal transport induces the 
degeneration of motor neurons (LaMonte et al., 2002; Teuling et al., 2008). Mutations in the 
dynactin subunit p150glued were discovered in familiar forms of motor neuron disease, 
including ALS and distal spinal and bulbar muscular atrophy (Puls et al., 2003, 2005; Munch 
et al., 2004), as well as in Perry syndrome, a rare atypical form of Parkinson’s disease (Farrer 
et al., 2009; Wider et al., 2010). Moreover dynein itself is associated with human pathology, 
mutations in the gene encoding the dynein heavy chain (DYNC1H1) were found in Charcot-
Marie-Tooth disease axonal type 2 (Weedon et al., 2011), in spinal muscular atrophy with 
lower extremity predominance (SMA-LED) (Harms et al., 2012; Scoto et al., 2015) and in 
malformations of cortical development (Poirier et al., 2013). 
Several lines of evidence suggest that altered axonal transport and dynein contribute to 
the pathogenesis of HD. Swollen axons and accumulated vesicular proteins were found in HD 
patient tissue also in several animal models of HD (Chevalier-Larsen and Holzbaur, 2006; 
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Morfini et al., 2009). Dynein, as well as p150Glued, are binding partners of HTT and of 
huntingtin associated protein 1 (HAP1) (Li et al., 1995; Li et al., 1998). Moreover, the activity 
of the dynein complex is positively regulated by wild-type HTT, and strongly decreased by 
mutant HTT (Caviston et al., 2007; Gauthier et al., 2004). However, the effects of mutant 
HTT on axonal transport are widespread by affecting both anterograde and retrograde fast 
axonal transport (Morfini et al., 2009).  
The existence of mouse strains bearing mutations in the dynein heavy chain gene 
(Dync1h1) provides an advantage to investigate the role of dynein in neurodegeneration in 
vivo. There exist currently three mouse strains, Legs at odd angles (Loa) and Cramping (Cra) 
were created by N-ethyl-N-nitrosourea (ENU) mutagenesis, both have a point mutation in 
Dync1h1 (Hafezparast et al., 2003), while Sprawling (Swl) bears a radiation-induced 9-bp 
deletion in the gene (Chen et al., 2007). Both mutations are located in the domain involved in 
homodimerization of the molecular motor. It was shown in Loa/Loa embryos that the 
mutation impairs the ability of dynein to sustain fast retrograde transport (Hafezparast et al., 
2003), also leads to decreased retrograde transport in adult dynein mutant motor neurons 
(Perlson et al., 2009). The three mouse strains have similar phenotypes: homozygous pups die 
before or within 24 hours of birth, heterozygous mice show unusual twisting of the body, hind 
limb clasping when held by the tail, develop abnormal gait and have a normal life-span 
(Hafezparast et al., 2003; Chen et al., 2007). Initially it was suggested that Cra/+ and Loa/+ 
mice display lower motor neuron degeneration, but these findings were not reproduced. On 
the contrary, a proprioceptive sensory neuropathy was observed in these mice (Ilieva et al., 
2008; Dupuis et al., 2009; Chen et al., 2007). However we think that this could not fully 
explain the mouse phenotype and aimed at a more detailed characterisation.  
 
I.3. Mitochondria in neurodegeneration 
Mitochondria are the main energy source of cells and tissues as they provide the 
production of ATP via oxidative phosphorylation. Besides this major function they play many 
other roles, such as contributing to cellular stress responses, production of reactive oxygen 
species (ROS), regulating homeostatic signalling pathways, house parts of the pyrimidine and 
lipid biosynthesis and modulate Ca2+ flux (Nunnari and Suomalainen, 2012). They adopt to 
the cell's changing energetic needs and protect it from oxidative damage. Therefore 
mitochondria are key regulators of cell death and survival. They are especially important in 
tissues with high energy demands like the brain and muscles. Multiple lines of evidence 
indicate that mitochondrial dysfunction is an early, active, common contributor to all major 
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neurodegenerative diseases (Lin and Beal, 2006; Nunnari and Suomalainen, 2012). Mutations 
in mitochondrial DNA (mtDNA) or nuclear-encoded mitochondrial proteins cause a 
heterogeneous group of different diseases, including neurodegenerative and metabolic 
disorders (Nunnari and Suomalainen, 2012). 
Mitochondrial dysfunction and oxidative stress are also early signs in HD and there is a 
strong evidence for their causal involvement in the pathogenesis. Toxicological studies with 
3-nitropropionic acid (3-NP) and malonate, that selectively inhibit succinate dehydrogenase 
(complex II), have long established that striatal neurons are exquisitely vulnerable to 
mitochondrial dysfunction (Beal et al., 1993; Ludolph et al., 1991). Mutant HTT can affect 
mitochondrial function directly and indirectly (Lin and Beal, 2006). It directly alters the 
calcium signalling at the mitochondrial membrane leading to a calcium influx into the 
cytoplasm, which is a potent pro-apoptotic signal postulated to directly lead to cell death 
(Panov et al., 2002; Tang et al., 2005). Indirectly, mutant HTT could affect mitochondrial 
function by transcriptional dysregulation (Sugars and Rubinsztein, 2003). It interacts with 
several transcription factors and coactivators, including CREB-binding protein, Sp1 and 
TATA binding protein, p53 and peroxisome proliferator-activated receptor (PPAR) gamma 
coactivator 1 alpha (PGC-1α) (Cha, 2007). 
Peroxisome proliferator-activated receptor (PPAR) gamma coactivator 1 alpha (PGC-
1α) is a transcriptional coactivator that regulates mitochondrial biogenesis and metabolic 
pathways. PGC-1α was discovered as a key regulator of adaptive thermogenesis which is a 
key component of energy expenditure in mammals (Puigserver et al., 1998). PGC-1α 
orchestrates in a promoter specific manner the activity of a wide range of important 
transcription factors such as PPARs, estrogen receptor and retinoic acid receptor. Through the 
regulation of these and other transcription factors, PGC-1α plays a key role in coordinating 
the expression of a wide range of nuclear encoded mitochondrial proteins. Due to this key 
position in the metabolic regulatory network PGC-1α is labelled as a “master regulator” of 
respiration and mitochondrial biogenesis (Canto et al., 2009; Handschin and Spiegelman, 
2006; Handschin 2009). 
PGC-1α exists in multiple isoforms, that fall into three major families: full length 
isoforms (FL) that are canonical isoforms including PGC-1α1, N terminal truncated isoforms 
(NT) that include the recently described NT- PGC-1α and PGC-1α4, and internally truncated 
(IT) isoforms such as PGC-1α2 and 3, that do not include exons 3-5 (Ruas et al., 2012; Zhang 
et al., 2009). Interestingly, the different PGC-1α functions are at least partially segregated 
among the different isoforms with FL-PGC-1α being more specialized in increasing 
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mitochondrial biogenesis, and NT-PGC-1α being more involved in muscle anabolism (Ruas 
et al., 2012).  
One important step which proposed PGC-1α for neurodegeneration, especially HD was 
the generation and analysis of animal models with genetically modified PGC-1α expression. 
Independently, two research teams developed PGC-1α knock-out mouse model (Leone et al., 
2005; Lin et al., 2004). Later it turned out that while knock-out mice from Lin and 
collaborators are complete PGC-1α knock-out (Ruas et al., 2012; Lin et al., 2004), mice from 
Leone et al. are only knock-out for FL-PGC-1α preserving all IT-isoforms and however NT-
isoforms are truncated for the 16 C-terminal amino-acids they show a roughly preserved 
function (Leone et al., 2005; Chang et al., 2012). These mice will thus be termed as FL-PGC-
1α -/- mice. The differences between the two PGC-1α knock-out models are due to different 
methods used for the PGC-1α gene targeting. Both research groups reported that their 
respective mouse lines display several metabolic abnormalities, such as cold intolerance and 
impaired body weight regulation. Moreover they share many phenotypical similarities to 
transgenic mouse models of HD. Mice show hind limb clasping, dystonic posturing, stimulus-
induced myoclonus and an exaggerated startling response. Whereas one strain exhibits 
profound hyperactivity (Lin et al., 2004), the other shows increased anxiety levels (Leone et 
al., 2005). At the histopathological level, both mouse strains display spongiform-like 
vacuolization predominantly in the striatum, and – less consistently – in other brain regions, 
such as the hippocampus or the pyramidal cells of the cortex (Leone et al., 2005; Lin et al., 
2004). In the striatum strong immunoreactivity for glial fibrillary acidic protein (GFAP) was 
detected, indicating gliosis (Lin et al., 2004). Further, more detailed neuropathological 
examination revealed that FL-PGC-1α -/- mice do not show immunostaining for a wide range 
of neurodegeneration-related proteins and rather suggested to model mitochondrial 
encephalopathies (Szalárdy et al., 2013). 
Further investigations provided more direct evidence of a role for PGC-1α function in 
the pathogenesis of HD (McGill and Beal, 2006). Profound temperature dysregulation was 
detected in HD transgenic mice and positive regulation of PGC-1α dependent genes, 
including uncoupling protein 1, was attenuated in brown adipose tissue (BAT) (Weydt et al., 
2006). Moreover mutant HTT supresses the expression of PGC-1α by interfering with the 
formation of a key transcription complex, the CREB/TAF complex (Cui et al., 2006). It was 
shown that genetic ablation of PGC-1α aggravates the phenotype of a knock-in HD mouse 
model and in vivo transfection with PGC-1α can rescue some aspects of the striatal pathology 
in the R6/2 transgenic HD mice (Cui et al., 2006). The clinical significance of the PGC-1α 
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system for HD is demonstrated by that common variants of the PPARGC1A gene are 
associated with a significant delay in onset of motor symptoms in HD patients of several 
years (Weydt et al., 2009, 2014; Taherzadeh-Fard et al., 2009; Soyal et al., 2012).  
Increased mitochondrial mass is frequently observed in human diseases directly or 
indirectly involving mitochondrial dysfunction (Michel et al., 2012), and is usually called 
“mitochondrial proliferation”. It is considered as a compensatory mechanism mitigating a 
compromised energy metabolism (Michel et al., 2012). Consistent with this view, muscle 
overexpression of FL-PGC-1α, leading to remarkable mitochondrial proliferation, is broadly 
protective for muscle function in mitochondrial myopathies (Wenz et al., 2008; Dillon et al., 
2012), also in amyotrophic lateral sclerosis (Da Cruz et al., 2012). Albeit mitochondrial 
proliferation might also be detrimental through alterations of mitochondrial regulatory 
functions such as apoptosis, calcium metabolism or oxidative stress. Increased mitochondrial 
mass was found to be associated with apoptotic features in muscle fibers (Aure et al., 2006) 
and forced mitochondrial biogenesis leads to muscle atrophy and dilated cardiomyopathy 
(Miura et al., 2006; Lehman et al., 2000). Indeed, increasing mtDNA through transgenic 
overexpression of Twinkle and Tfam, two factors that regulate mtDNA replication was 
deleterious for respiratory chain activities (Ylikkallio et al., 2010). Mechanisms underlying 
mitochondrial proliferation are unknown. Both increased mitochondrial biogenesis (Lin et al., 
2002) or decreased mitochondrial autophagy (Masiero et al., 2009) are sufficient to increase 
mitochondrial mass. Whether one of these mechanisms, or both, are involved to evoke 
mitochondrial proliferation in disease conditions remains unknown. 
Recently, others from our workgroup showed that the Cramping mice develop systemic 
mitochondrial dysfunction with ragged red fibers (Eschbach et al., 2013). Moreover, 
increased mitochondrial mass accompanied by PGC-1α activation was detected.  
An important opportunity provided by the existence of animal models of 
neurodegenerative diseases is the test of supposed protective agents. One possible candidate is 
L-carnitine (LC) which has antioxidant properties and is used to improve mitochondrial 
function. LC is a nutrient also synthesised in vivo from the amino acids lysine and 
methionine, however 75% comes from dietary sources (Steiber et al., 2004). The main role of 
LC is in cellular energy metabolism, it improves mitochondrial energetics and scavenges free 
radicals (Calabrese et al., 2012). It plays a role in the transport of long-chain fatty acids into 
the mitochondria for beta-oxidation, providing energy and acetyl-coenzyme A (CoA) 
formation. On the other hand, it contributes to the removal of short- and medium-chain fatty 
acids preventing these toxic accumulation in the mitochondria and leading to an increase of 
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free CoA (Calabrese et al., 2012). Thus, it controls the mitochondrial acetyl-CoA/ CoA ratio 
which is crucial for mitochondrial metabolism.  
Animal experimental data suggested long ago that LC may have antioxidant properties 
(Koudelova et al., 1994). It can reduce oxidative stress in aged animals (Poon et al., 2006, 
Long et al., 2009; Rani and Panneerselvam, 2002; Savitha et al., 2005) and acts as a free 
radical scavenger (Arockia Rani and Panneerselvam, 2001). LC also improves age-related 
oxidative DNA damage, nucleic acid status and mitochondrial enzymes activity in aged rats 
(Haripriya et al., 2004; 2005; Juliet et al., 2005). LC was found to be protective against 
nickel-induced neurotoxicity in Neuro-2a cell line via attenuating the harmful ROS and 
malondialdehyde level elevation, ATP reduction and disrupted mitochondrial membrane 
potential (He et al., 2011). Also it prevented peroxynitrite and free radicals production 
induced by methamphetamine in adult male mice (Virmani et al., 2002). Moreover acetyl-LC 
modulates endogenous cellular defence mechanisms and stress response by inducing heat-
shock proteins (HSPs), heme oxygenase 1 and SOD2 and prevents age-related changes in rats 
(Calabrese et al., 2006; 2010).  
A double-bind placebo controlled human study did not find any significant changes in 
HD patients as compared with healthy subjects that upon low dose L-carnitine (Goety et al., 
1990). We suggested that LC may be effective in higher doses.  
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II. Aims 
We investigated the role of the molecular motor dynein and mitochondrial dysfunction in 
neurodegeneration using different experimental mouse models. 
 
The aims of our studies were as follows: 
(i) to provide a direct genetic evidence linking cytoplasmic dynein mutation to striatal 
dysfunction by detailed characterisation of Cramping mice bearing a point mutation in the 
dynein heavy chain 1 gene.  
 
(ii) to study whether the recently showed systemic mitochondrial dysfunction (Eschbach et 
al., 2013) and compensatory mitochondrial proliferation in Cramping mice is FL-PGC-1α 
dependent. We investigated the effect of FL-PGC-1α ablation in Cramping mice with 
extended characterisation of the phenotype using longitudinally performed behavioural tests, 
muscle histology, electron microscopy.  
 
(iii) to study whether L-carnitine administration, in high dose, exerts beneficial effects on the 
survival as well as the behavioural and neuropathological phenotype in N171-82Q transgenic 
mouse model of HD. 
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III. Materials and methods 
III. 1. Animals 
We used different experimental mouse models such as Cramping mice carrying a point 
mutation in the dynein heavy chain 1 gene, FL-PGC-1α -/- mice and the N171-82Q transgenic 
mouse model of HD.  
Heterozygous Cra/+ mice were obtained from Ingenium Pharmaceuticals AG, 
Martinsried, Germany. They were identified by tail DNA genotyping as previously described 
(Hafezparast et al., 2003). Wild-type littermates were used as controls. FL-PGC-1α -/- mice 
were obtained from Prof. Daniel Kelly (Leone et al., 2005). They were initially published as 
full PGC-1α -/- mice but newer results of our workgroup and those of others (Chang et al., 
2012) show that these mice are only ablated for full length PGC-1α. We created Cramping 
FL-PGC-1α -/- (referred as Cra/FLα -/-) mice in two crossing steps and used F1-generation 
mice of the four genotypes in the same B6C3He-hybrid background. N171-82Q mice were 
originally obtained from Jackson Laboratories (Maine, USA) and backcrossed to the B6C3F1 
background. The offspring were genotyped by using a PCR assay on the tail DNA at the age 
of 4 weeks. Animals were maintained in a temperature- and humidity-controlled environment 
on a 12h light/dark cycle and received food and water ad libitum.  
For histological analysis, animals were deeply anesthetized with 1 mg/kg body weight 
ketamine chlorhydrate and 0.5 mg/kg body weight xylazine or with isoflurane (Abott 
Laboratories Ltd., Queenborough, UK), and transcardially perfused with 4% 
paraformaldehyde in 0.1 M pH 7.4 phosphate buffer. Tissues were then quickly dissected, 
post-fixed for 24 hours in 4% paraformaldehyde, and cryoprotected for 48 hours with 30% 
sucrose or 10% glycerol in PBS before cryostat sectioning. For biochemical analysis, animals 
were sacrificed and tissues were quickly dissected, snap frozen in liquid nitrogen and stored at 
-80°C until use.  
All animal experiments were performed under the supervision of authorized 
investigators, followed current EU regulations and were approved by the local animal care 
committee.  
 
III. 2. Measurement of body temperature and weight 
In Cra/FLα -/- and the 3 comparative mouse groups body temperature was monitored 3 
times every week from the age of 6 weeks as described previously (Weydt et al., 2006) at 
noon with a telemetry system using subcutaneously implanted transponders placed in the 
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interscapular space (Bio Medic Data Systems, Seaford, DE, USA). At the same time body 
weight was also measured. 
 
III. 3. Testing of motor performance and behaviour 
One week before the start of the tests, animals were brought to the behavioural analysis 
facility and handled every day. Only male mice were used for behavioural tests. A battery of 
behavioural tests were performed at 3 and 12 months of age in the study comparing Cra/+ 
versus wild-type mice including the following tests: grip strength, rotarod, open field, 
elevated plus maze, Morris water maze. Whereas the cohorts of the Cra/+, FL-PGC-1α -/- 
crossbreeding study were tested longitudinally from 2 to 12 months of age with the range of 
slightly different tests: modified SHIRPA, grip strength, rotarod, open field, elevated plus 
maze, string agility.  
Modified SHIRPA protocol (Rogers et al., 2001) was used to detect the overall 
neurological phenotype of the mice.  
Muscle grip strength was measured using a Bioseb gripmeter (Vitrolles, France) on 
forelimbs and all limbs. Each assay was performed in triplicate and measurements were 
averaged.  
The rotarod test was used to assess motor coordination and balance. Mice had to keep 
their balance on a rotating rod at a continuous acceleration from 4 to 40 rpm in 300 s (Rotarod 
Version 1.2.0. MED Associates Inc., St. Albans, VT). The time (or latency) it took the mouse 
to fall off the rod was measured. Each mouse had to perform 3 trials separated by 15 minutes 
each other, and the 3 trials were averaged.  
To identify differences in locomotor activity and exploratory behaviour, mice were 
tested in the open field. In this test, animals were placed at the border of a square arena (50 
cm x 50 cm) and allowed to explore the arena freely. The exploration time was 30 minutes in 
the study comparing Cra/+ versus wild-type mice and 10 minutes in the cohorts of PGC-1α 
ablation in these mice. Locomotor activity was assessed by the total distance moved and the 
average velocity. To determine the exploratory behaviour, the number of rearings was 
measured. Open field was also performed in the N171-82Q transgenic HD mice in a slightly 
different apparatus as described later.  
To assess anxiety, mice were evaluated using an elevated plus maze paradigm. The 
maze was elevated 92 cm above the floor, and consisted of 4 arms of 30 cm x 5 cm each, 
including 2 opposite ‘‘closed’’ arms surrounded by dark walls and 2 opposite ‘‘open’’ arms 
exposed without any walls. The centre of the maze was a 5 cm x 5 cm common area. Each 
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mouse was placed for a single trial at the centre of the maze facing a closed arm, and allowed 
to explore the maze freely for a period of 5 min. The amount of time (in seconds) spent in 
both the open arms and closed arms was recorded.  
To measure reference learning (acquisition) and memory (retention), the Morris water 
maze was performed. The device consisted of a circular pool of 120 cm diameter, filled with 
water (25-27°C), which was made opaque by adding 2 liter of milk. The pool was divided 
into 4 equal-sized quadrants and was surrounded by grey curtains covered with various visual 
cues, which helped the mice to orient their location in the pool. A 10 cm platform was placed 
in the quadrant A, such that the platform was 1 cm below the water surface and visually 
indiscernible to the animals. On each trial, mice were allowed to swim for a maximum of 60 s 
and were released from 4 different defined positions. If the animal failed to discover the 
location of the platform in 60 s, it was guided to the platform and then allowed to stay for 30 
s. After removal, mice were placed under an infrared lamp and allowed to warm up and dry 
off. The test was divided into 2 phases, an acquisition phase (18 trails, six/day), followed by a 
reversal phase during which the platform was moved to the opposite quadrant (12 trails, 
six/day). Escape latency and swum distance were analysed during both acquisition and 
reversal learning, and 2 successive trials were averaged into one block. All paths were tracked 
and analysed with an electronic imaging system (Viewer 2.2.0.55, BIOBSERVE GmbH, 
Bonn, Germany) at a frequency of 15 Hz and a spatial resolution of 720 x 576 pixels.  
String agility test was performed to access forepaw grip capacity and agility. Mice were 
placed in the centre of a 50 cm long string suspended about 33 cm above a padded surface 
between two platforms. Mice were allowed to grip the string with only their forepaws and 
then released for a maximum of 60 sec. A rating system, ranging between 0 and 5, was 
employed to assess string agility for a single 60 sec trial (0=animal unable to remain on string, 
1=hangs by two forepaws, 2=attempts to climb onto string, 3=two forepaws and one or both 
hindpaws around string, 4=four paws and tail around string, with lateral movement, 5=escape 
to the platform). As both Cramping and Cra/FLα  -/- mice showed a severe defect in muscle 
string agility (from early age score 0) we further detected the time spent on the string till 
falling down giving the maximum of 60 sec for the mice who reached the platform during the 
trial. 
 
III. 4. Real time (RT) qPCR 
Total RNA was extracted using Trizol (Invitrogen, Cergy-Pontoise, France) according 
to the manufacturer's instructions. cDNA synthesis was performed using 1 µg of total RNA 
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(iScript cDNA Synthesis kit; Bio-Rad, Marne La Coquette, France). PCR analysis was carried 
out as described (Dupuis et al., 2009) on a Bio-Rad CFX96 System using iQSYBR Green 
Supermix. A specific standard curve was performed for each gene in parallel, and each 
sample was quantified in duplicate. PCR conditions were 3 min at 94°C, followed by 40 
cycles of 45 s at 94°C and 10 s at 60°C. Data were analyzed using the iCycler software, and 
normalized to the reference genes encoding either the 18S ribosomal subunit and the RNA 
polymerase II mRNA.  
 
III. 5. In vivo brain imaging 
Magnetic resonance imaging (MRI) was performed in the In-vivo-Imaging Laboratory 
of Boehringer Ingelheim Pharma GmbH & Co. KG Biberach, Germany. MRI data were 
acquired on a Bruker Biospec 47/40 scanner (Bruker BioSpin, Ettlingen, Germany) at 4.7 
Tesla. Acquisitions were performed at 5 and 10 months of age, respectively (Cra/+, wild-type 
mice, n = 20). Mice were anaesthetized through continuous inhalation of 1.2-1.5% isoflurane 
(in 70:30 N2O:O2) and fixed in a stereotactic head holder. For anatomical analysis of the 
mouse brain contiguous sets of 6 horizontal T2-weighted images were acquired using a RARE 
sequence with slice thickness 600 μm (no gap). Data processing was performed via voxel-
based volumetry by the in-house developed software package Tissue Classification Software 
(TCS). The analysis was blinded, evaluated by the same experienced investigator. The 
striatum was identified in 4 consecutive horizontal slices as compared with the Mouse Brain 
Library (http://www.mbl.org/mbl_main/atlas.html) between Bregma: -3,24; Interaural: 6,76 
and Bregma: -5,04; Interaural: 4,96. The lateral ventricles were identified in the same 
horizontal sections by semi-automated region growth.  
Positron emission tomography (PET) imaging was performed on a Siemens Inveon 
small animal PET/CT system (Siemens Preclinical Solutions, Knoxville, TN, USA) using the 
D1 receptor ligand [11C] SCH-23390 or the D2/3 receptor ligand [18F]Fallypride with slightly 
different methods (for a detailed description see Appendix I., Braunstein et al., 2010). For 
[11C] SCH-23390 PET imaging 5 wild-type and 5 Cra/+ mice were used, for [18F]Fallypride 
PET measurements 10 animals of each group (Cra/+ and wild-type) were randomly selected 
at 10 months of age. Mice were anesthetized and a 60 minute emission scan was performed 
starting with bolus injection of the radioactively labelled specific receptor ligand via a tail 
vein catheter. The Simplified Reference Tissue Model (SRMT) (Lammertsma et al., 1996) 
was used to calculate the binding potential. Regions-of-interest were defined on co-registered 
PET/CT images.  
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III. 6. Analysis of brain astrocytosis 
Brain sections comprising the anterior part of the caudate nucleus and the putamen 
were cut on a vibratome at a thickness of 50 µm (Leica Microsystems, Wetzlar, Germany) 
and were stained by indirect immunofluorescence, using an antibody directed against the 
specific astrocyte marker glial fibrillary acidic protein (GFAP, Santa Cruz Biotechnology, 
Heidelberg, Germany) following the manufacturer’s instructions. Quantitative analysis of 
immunoreactivity was performed using ImageJ. 
 
III. 7. Stereological analysis of DARPP32 neurons 
Coronal sections were cut in six series at a thickness of 35 µm throughout the brains 
using a freezing microtome. One series of free-floating brain sections were processed for 
immunohistochemistry with a primary rabbit antibody against DARPP32 (1:1000, Chemicon, 
AB 1656) (Bode et al., 2008). Stereological estimations of the total number of DARPP32 
positive neurons in the striatum were performed unilaterally on blind-coded slides with the 
Computer Assisted Toolbox Software (New CAST) module in VIS software (Visiopharm, 
Horsholm, Denmark) by applying the optical fractionator principle (West et al., 1991). 
 
III. 8. mtDNA quantification 
Total DNA was extracted from muscle using standard methods. The content of mtDNA 
was determined using real-time quantitative PCR using 100 ng of purified DNA by measuring 
the threshold cycle ratio (ΔCt) of a mitochondrial-encoded gene Cox1 versus the nuclear-
encoded gene Ppia (cyclophilin A). 
 
III. 9. Muscle histology and electron microscopy 
For muscle histology, isopentane frozen samples were cut on a cryostat into slices 
16µm thick and processed for succinate dehydrogenase (SDH) staining using standard 
pathological stainings. For electron microscopy (EM) analysis, 12 months old mice were 
sacrificed and muscle tissues were quickly dissected and fixed with 2,5% glutaraldehyde, 
10% sucrose fixative. Samples were post-fixed, dehydrated, embedded in Epon, and sectioned 
for EM. EM was performed at the Central Electron Microscopy Department at the University 
of Ulm. 
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III. 10. L-carnitine administration in N171-82Q mice 
III. 9. 1. Survival 
Thirty transgenic N171-82Q mice were used in this experiment. Eleven animals 
received intraperitoneal (i.p.) injections of L-carnitine (Biocarn, MEDICE, Iserlohn, 
Germany) at a dose of 250 mg/bodyweight kg (diluted in 0.15 ml, pH 7.4) 5 times a week 
starting at 6 weeks of age until death; 19 animals received an i.p. injections of the vehicle of 
L-carnitine in the same volume at the same times.  
III. 9. 2. Open-field test  
A separate set of 6-week-old transgenic mice were used for behavioural studies. The 
same experimental protocol and drug administration were used as above (n= 7 per group). 
The Conducta system and programme (Conducta 1.0; Experimetria Ltd., Hungary) were used  
to detect and evaluate the changes in spontaneous motor activity and exploration activity in 
the open-field paradigm. Each mouse was placed in the centre of a square arena (48x48x40 
cm) and its behaviour was recorded for 5 minutes with the Conducta software. The 
ambulation distance, mean velocity, duration of immobility and number and duration of 
rearings were recorded. Tests were performed once a week for 10 weeks at the same time of 
the same day in order to avoid alterations due to the diurnal rhythm. 
III. 9. 3. Immunohistochemistry 
30-microm thick cryostat sections were cut to obtain sections from the entire striatum 
from 16 weeks old mice. Serial sections were immunostained with a polyclonal antibody 
recognizing the first 256 amino acids of human huntingtin (EM48, Chemicon International 
Inc., Temecula, CA, USA) at dilutions of 1:500. The specificity of the immune reactions was 
controlled by omitting the primary antiserum. An additional series of sections from each case 
were Nissl-stained with cresyl violet. 
 
III. 11. Statistical analysis 
Data are expressed as the mean ± SEM. Statistical analysis was accomplished using 
non-parametric Student t-test or ANOVA followed by Newman-Keuls multiple comparisons 
test (PRISM version 4.0b; GraphPad, San Diego, CA). Kaplan-Meier analysis and the 
Mantel-Cox log rank test were used to determine the survival differences between groups in 
N171-82Q mice. Differences at P < 0.05 were considered significant. 
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IV. Results 
 
The motor phenotype of Cra/+ mice is characterized by early muscle weakness, 
progressive incoordination and hyperactivity 
We first performed a battery of motor and behavioural tests in Cramping mice (Cra/+). 
Cra/+ mice showed reduced total and forelimb muscle grip strength compared with wild-type 
mice as early as 3 months of age (figure 1A), and suffered from an impairment in motor 
coordination that mildly increased with aging, as observed using an accelerating rotarod test 
(figure 1B).  
 
 
 
Figure 1. Locomotor and behavioural abnormalities in Cra/+ mice compared with wild-type mice (+/+) 
A. Grip muscle strength of forelimbs (left panel) and all limbs (right panel)  
B. Latency to fall in an accelerating rotarod test  
C. Track length (left panel) and average velocity (right panel) in an open field  
D. Time spent in closed arms (upper panel) and open arms (lower panel) in an elevated plus maze test  
E. Time spent (upper panels) and distance swum (lower panel) to reach the hidden platform in a Morris water 
maze test at 3 (left panel) and 12 (right panel) months of age. The platform was in position A during the first 3 
days of the test, and then moved to position C for the last two days.  
***P<0.001 versus corresponding wild-type, #P<0.05 versus 3 months old Cra/+ mice (n=12 mice per group), 
*P<0.05 versus corresponding wild-type. 
    
23 
Cra/+ mice displayed hyperactivity in the open field arena as revealed by increased track 
length and average velocity (figure 1C). No differences were observed in the number of 
rearings, indicating normal vertical behaviour (data not shown). The level of anxiety appeared 
similar between Cra/+ mice and their wild-type littermates as assessed using the elevated plus 
maze paradigm (figure 1D). In the Morris water maze test, Cra/+ mice tended to spend more 
time in reaching the platform at 12, but not 3 months of age, as compared to wild-type 
animals. This was likely due to impaired motor incoordination rather than to spatial memory 
deficits since the observed difference between genotypes was annulled when considering the 
distance swum by the mice (figure 1E). Taken together, Cra/+ mice display muscle weakness 
and incoordination with increased open field activity in the absence of anxiety and obvious 
spatial working memory deficits. 
 
Cra/+ mice present with striatal atrophy and lateral ventricle enlargement 
We found that forebrain, but not hindbrain, wet weight was decreased in Cra/+ mice 
(figure 2A), suggestive of atrophy. The striatum and cerebral cortex of Cra/+ mice appeared 
grossly normal using haematoxylin/eosin staining (figure 2B), and the cortical layer 
organisation was preserved (figure 2C), suggesting that the defect was not due to abnormal 
cortical development. In vivo brain imaging using MRI showed a significant reduction in the 
volume of the Cra/+ mice striata at both 5 and 10 months of age (figure 2D-E), while, 
concomitantly, the volumes of the lateral ventricles were significantly increased (figure 2D, 
F). Thus, mutation in dynein leads to striatal atrophy in mice. 
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Figure 2.  Striatal atrophy in Cra/+ mice 
Wild-type mice (+/+) are in empty columns, Cra/+ mice in black columns 
A. Wet weight of hindbrain (left) and forebrain (right) at 12 months of age. *P<0.05 versus corresponding wild-
type (n=4 mice per group). B. Low magnification photomicrographs of haematoxylin and eosin staining at 18 
months of age. CC: corpus callosum. Scale bar = 100 µm. C. Higher magnification of B showing the aspect of 
the six layers of the cortex. Scale bar = 50µm. D. Representative horizontal T2-weighted MRI slices at 5 and 10 
months of age. Note the enlargement of the lateral ventricles of the Cra/+ mouse. E. Striatal volume of at 5 (left) 
and 10 (right) months of age. ***P<0.001 versus corresponding wild-type (n=20 mice per group). F. Lateral 
ventricle volume at 5 (left) and 10 (right) months of age. ***P<0.001 versus corresponding wild-type (n=20 
mice per group). 
 
Progressive astrocytosis in the absence of neurodegeneration in the striatum 
Reactive astrocytosis represents a typical marker of neuronal stress and is often a sign 
of an underlying pathology. Interestingly, reactive astrocytosis, as revealed by glial fibrillary 
acidic protein (GFAP) immunoreactivity (figure 3A), was dramatically increased in the 
striatum of 8 months old Cra/+ mice, and this increase was even higher at 18 months of age 
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(figure 3B). Consistent with this observation, striatal GFAP mRNA levels as measured using 
RT-qPCR were higher in Cra/+ mice than in wild-type littermates at 8 months, but not at 4 
months of age (Figure 3C). 
 
 
 
 
 
Figure 3: Progressive striatal 
astrocytosis in Cra/+ mice 
A. Representative microphotographs 
showing haematoxylin/eosin staining 
(left panels) and GFAP 
immunoreactivity (right panels) in the 
striatum from wild-type mice (+/+, 
upper panels) and Cra/+ mice (lower 
panels) at 18 months of age. Scale bar = 
25µm.  
B. Quantification of the surface 
occupied by GFAP positive cells in the 
striatum at 8 and 18 months of age. Data 
are expressed as percentage of the total 
surface in the picture. *P<0.05 versus 
indicated condition (n=5 mice per 
group).  
C. mRNA levels of GFAP in the 
striatum at 4 and 8 months of age. 
*P<0.05 versus wild-type (n=5-7 mice 
per group). 
 
 
 
To determine whether astrocytosis was associated to neurodegeneration, we determined 
the total number of DARPP32 (dopamine and cAMP regulated phosphoprotein of a molecular 
weight of 32 kDa) positive medium spiny neurons (MSNs), the neuronal population 
comprising more than 95% of striatal neurons, using stereological analysis. The analysis of 
DARPP32 positive MSNs showed a non-significant trend towards decreased number at 6 
months of age (figure 4). These data show that the phenotype of dynein mutant mice is rather 
due to neuronal dysfunction than to neurodegeneration in the striatum. 
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Figure 4: No significant neuronal loss in the striatum of Cra/+ mice.  
A and B. Representative photographs of striatal sections processed for DARPP32 immunohistochemistry from 
wild-type mice (+/+) at 6 months of age as well as Cra/+ mice at 6 and 18 months of age.  
C. Stereological estimations of the total number of DARPP32 positive neurons in the unilateral striatum did not 
reveal any statistically significant differences between the groups (n= 4–6 mice per group) 
 
Altered dopamine signalling and D1 receptor binding in the striatum of Cra/+ mice 
D1, but not D2, dopamine receptor mRNA levels were decreased in 8 months old Cra/+ 
mice as shown using RT-qPCR (figure 5A). D1 receptor expressing cells synthesize substance 
P, whereas D2 receptor expressing cells synthesize pre-proenkephalin. We found that 
substance P, but not pre-proenkephalin, mRNA levels appeared decreased in 8 months old 
Cra/+ mice (figure 5A), which corroborates the selective down-regulation of the expression 
of D1 dopamine receptors in striatal neurons. In addition, we performed positron emission 
tomography (PET) analysis of the binding of the D1 receptor selective ligand [11C] SCH-
23390 (figure 5B). Quantification of [11C] SCH-23390 showed a decrease of the signal in the 
brains of Cra/+ mice (figure 5C), which further reinforces the presence of striatal 
dopaminergic impairment. We extended our D1-PET scans by using [18F]Fallypride, a high-
affinity selective dopamine D2/3 receptor ligand with the advantage of long half-life 
compared to [11C]Raclopride (Siessmeier et al., 2005). We observed a significant reduction of 
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[18F]Fallypride uptake in the striatum of Cra/+ mice compared with wild type animals (figure 
5D), lending further support for the involvement of the striatal dopaminergic system in the 
Cra/+ pathogenesis.  
 
 
Figure 5. Altered dopamine signalling and binding in the striatum of Cra/+ mice 
A. mRNA levels of the dopamine D1 and D2 receptor, substance P and pre-proenkephalin in the striatum of 
wild-type mice (+/+) and Cra/+ mice at 4 and 8 months of age. *P<0.05 versus wild-type (n=5-7). 
B. Representative [11C]SCH-23390 images (all frames averaged together) through the striatum of a wild-type 
mouse brain (+/+, upper panels) and a Cra/+ mouse brain (lower panels) are shown. 
C. Binding potentials (BPND) of [11C]SCH-23390 (n=5) and [18F]Fallypride (n=10) calculated using SRTM. 
*P<0.05 versus wild-type. 
 
In all, we showed that Cramping mice bearing a point mutation in the molecular motor 
dynein display striatal dysfunction which can better explain the phenotype observed in these 
mice. Thus, our findings support the role of dynein and retrograde axonal transport in striatal 
pathology.  
 
Mitochondrial proliferation in Cramping mice is dependent on endogenous FL-PGC-1α  
To determine whether PGC-1α is functionally involved in Cramping induced 
mitochondrial proliferation, we ablated FL-PGC-1α in these mice. We chose FL-PGC-1α 
ablation as this isoform is more specialized in increasing mitochondrial biogenesis and pan-
PGC-1α ablation is very toxic per se for muscle physiology (Handschin et al., 2007). We 
crossed FL-PGC-1α -/- mice with Cramping mice to generate Cramping mice deficient in FL-
PGC-1α (termed Cra/FLα -/- mice in the rest of the thesis).  
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The ablation of FL-PGC-1α in Cramping mice completely abolished the previously 
observed increases in mtDNA levels in muscles (figure 6A). At 6 months of age, i.e. an age at 
which mitochondrial dysfunction is not histologically and biochemically evident in Cramping 
mice, we observed a 20% increase in citrate synthase activity in Cramping muscle, which was 
fully reverted by FL-PGC-1α ablation (figure 6B). This was associated with unchanged 
mitochondrial respiratory complex activities and normal ratios between respiratory chain 
complex activities (data not shown in the thesis; see Appendix II., Róna-Vörös et al., 2013) 
suggesting that mitochondrial proliferation maintained close to normal respiratory activity at 
that age. From an ultrastructural point of view, the Cramping mutation leads to giant 
mitochondria invading sarcomeres (Eschbach et al., 2013). FL-PGC-1α deficiency reverted 
this mitochondrial proliferation (figure 6C, quantifications in 6D-E). 
 
 
 
 
Figure 6. Mitochondrial proliferation 
in Cramping mice is dependent upon 
FL-PGC-1α 
+/+ mice are in blue, Cramping mice in 
red, FL-PGC-1α  -/-  in green and 
compound Cra/FLα -/-in brown. 
A. Mitochondrial DNA (mtDNA) levels 
in tibialis anterior muscle. **, p<0.01 ; 
***, p<0.001, ANOVA followed by 
Newman-Keuls as compared with the 
indicated condition. n=8 per group. 
B. Citrate synthase activity in 
nmol/min/mg protein in gastrocnemius 
muscles. **, p<0.01 ; ***, p<0.001, 
ANOVA followed by Newman-Keuls 
as compared with the indicated 
condition. n=3 per group. 
C. Representative electron micrographs 
of glycolytic gastrocnemius muscle of  
+/+ (left column) and Cramping (right 
column) mice in either FL-PGC-1α +/+ 
(upper row) or -/- (lower row) 
background. Pairs of mitochondria are 
found in the I-band on both sides of the 
Z-band in wild type mice. Note the 
large increase in size in the 
mitochondria of Cramping mice 
disrupting the alignment of sarcomeres 
that is reverted by ablation of PGC-1α. 
As previously observed mitochondria of 
FL-PGC-1α -/- mice are smaller. 
Arrows show pairs of mitochondria in 
each picture. Scale bar: 600 nm. 
D-E. Quantification of mitochondrial 
area (D) and perimeter in experiments 
presented in C. 
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Thus, mitochondrial proliferation in Cramping mice is fully dependent upon 
endogenous FL-PGC-1α and cannot be rescued by the roughly normal expression of NT-
PGC-1a in FL-PGC-1α -/- mice. 
 
Endogenous FL-PGC-1α mitigates overall phenotype and mitochondrial dysfunction in 
Cramping mice 
We next asked whether ablating the increase in mitochondriogenesis in Cramping mice, 
through FL-PGC-1α ablation, modified the phenotype of the mice. Cra/FLα -/- mice 
displayed a much more severe phenotype than single mutations. They showed prominent 
kyphosis, and abnormal posture as well as progressive hair loss (figure 7A). Both male and 
female Cra/FLα -/- mice displayed body weight loss as compared with the three other 
genotypes (figure 7B-C). Body temperature of Cra/FLα -/- mice became progressively lower 
in females (figure 7D-E) while in males the defect was also present in single FL-PGC-1α -/- 
mice. 
 
 
 
 
 
 
 
 
Figure 7. FL-PGC-1α  
ablation exacerbates 
global phenotype of 
Cramping mice 
+/+ mice are in blue, 
Cramping mice in red, 
FL-PGC1α  -/-  in green 
and compound Cra/FLα 
-/- in brown. 
A. Left : representative 
photographs of  3 weeks 
old littermate Cramping 
and Cra/FLα -/-mice 
Right : typical kyphosis 
and hair loss in a 12 
months old Cra/FLα -/-
mouse. 
B-E. Body weight (B, 
C) and body 
temperature (D-E) of  
male (B, D) and female 
(C,E) mice. **, p<0.01 
for Cra/FLα -/- as 
compared with the three 
other groups. N=7-8 per 
gender per group. 
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At 12 months of age, both single Cramping and FL-PGC-1α -/- muscles showed the 
expected decrease in SDH activity in both tibialis anterior (TA) and soleus muscles (figure 8). 
The combination of both mutations potently exacerbated this mitochondrial defect (figure 8).  
 
Figure 8. FL-PGC-1α ablation exacerbates mitochondrial dysfunction in Cramping mice 
Representative photomicrographs showing muscle sections of +/+, Cramping, FL-PGC-1α -/- and compound 
Cra/FLα -/- tibialis anterior (upper pictures) and soleus muscles from 12 months old mice stained for succinate 
dehydrogenase activity (SDH). Scale bar : 200 µm. n=4-5 per group. 
 
Endogenous FL-PGC-1α mitigates the neurological phenotype of Cramping mice 
The Cramping mutation leads to a stereotypical neurological phenotype that includes 
loss of muscle strength and incoordination as prescribed above. As compared with Cramping 
mice, Cra/FLα -/- mice showed an earlier and stronger loss of grip strength in forelimbs and 
all limbs (figure 9A-B). Tremor, a phenotype occasionally observed in Cramping or FL-PGC-
1α -/- mice after 9 months of age, occurred systematically before 6 months of age in Cra/FLα 
-/- mice (figure 9C). Indeed, compound transgenic mice were unable to hang on a string as 
early as 4 months of age, while Cramping mice were still able to do so at least 10 seconds 
until 9 months of age (figure 9D). Further supporting this point, compound transgenic mice 
showed profoundly impaired rotarod performance as compared with all three other genotypes 
at 6, 9 and 12 months of age (figure 9E) and decreased rearing activity at 8 and 12 months of 
age (figure 9F). 
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Figure 9. FL-PGC-1α  ablation exacerbates neurological phenotype of Cramping mice 
+/+ mice are in blue, Cramping mice in red, FL-PGC-1α  -/-  in green and compound Cra/FLα -/-in brown. 
A-B. Forelimb (A) and all limb (B) grip strength. **, p<0.01 for Cra/FLα -/-  as compared with Cramping mice 
(repeated ANOVA). n= 14-16 per group. 
C. Kaplan-Meier plot depicting the onset of tremors. P<0.001 for Cra/FLα -/-as compared all three other groups. 
(log rank test). n= 14-16 per group. 
D-E. String agility score (in seconds, D) and rotarod performance (E). **, p<0.01 for Cra/FLα -/- as compared 
with Cramping mice (repeated ANOVA). n= 14-16 per group. 
F. Number of rearings in a 30 minute open field test for mice at 8 or 12 months of age.*, p<0.05  for Cra/FLα -/- 
as compared with the indicated condition (ANOVA followed by Newman-Keuls). n=7-8 per group. 
 
In all, we demonstrated that FL-PGC-1α is required for mitochondrial proliferation 
compensatory occurred in Cramping mice with overall mitochondriopathy. Moreover ablation 
of FL-PGC-1α notably worsened the phenotype of Cramping mice. These data help for better 
understanding the pathomechanism of mitochondrial dysfunction in neurodegeneration.  
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L-carnitine administration significantly improved the survival and ameliorated the 
motor symptoms of N171-82Q mouse model of HD 
The mean of survival of the vehicle-treated transgenic mice was 125.6 days. LC 
treatment caused a significant increase of 14.91% in the survival time (144.3 days) (figure 
10).  
 
 
 
 
 
Figure 10. Survival times of the L-carnitine-treated and 
control transgenic mice. The Kaplan–Meyer survival curve 
revealed that the L-carnitine-treated animals exhibited an 
increased duration of survival as compared with the control 
group (*p<0.05). 
 
 
From the age of 14 weeks the N171-82Q transgenic HD mice started to move more 
slowly and less compared with wild-type mice in the open field apparatus. This decreased 
motility was completely reverted by LC administration (figure 11A-C). LC itself did not have 
any influence in wild-type mice mobility (figure 11A-C). Further, the frequency of rearing 
was significantly reduced in transgenic mice at the age of 15 weeks (*p<0.05) not in the L-
carnitine treated group (figure 11D). 
 
Figure 11. Behavioural assessment of LC treated transgenic mice in open-field tests. (A) Ambulation 
distance (*p<0.05); (B) mean velocity (*p<0.05); (C) immobility time (**p<0.01, *p<0.05); (D) rearing time 
(**p<0.01, *p<0.05). 
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L-carnitine treatment was neuroprotective in N171-82Q HD mice 
L-carnitine treatment also ameliorated the striatal neuronal atrophy in transgenic HD 
mice. Our quantitative analysis demonstrated that the LC-treated transgenic animals had a 
significantly higher (*p<0.05) number of surviving striatal neurons concerning cresyl violet-
staining relative to the vehicle-treated group (figure 12). Moreover we quantified the 
huntingtin-immunoreactive (IR) aggregates visualized by EM48 polyclonal antibody in the 
outer lamina of the pyriform cortex (layer II), which is an important area of the N171-82Q 
transgenic mice and within the lateral striatum. The EM48-IR aggregates were much more 
prominent within the cortex as compared with the neostriatum. In the L-carnitine-treated 
group fewer huntingtin aggregates were detected in both areas compared with the vehicle-
treated transgenic group. LC treatment significantly (**p<0.01) reduced the number of 
cortical aggregates. In the lateral striatum LC treatment induced a slight, but not significant 
decrease of the huntingtin-IR aggregates (figure 13). 
 
 
 
Figure 12. Cresyl violet-stained neurons in the striatum.  
Wild-type (wt) (A), control transgenic (tg) (B) L-carnitine-treated wt (C), and the L-carnitine-treated tg (D) 
groups. Scale bar = 25mm. Diagram shows the mean numbers of cresyl violet-stained neurons in the striatal area 
of the wild-type mouse (striped grey bar), the control tg mouse (light bar), the control L-carnitine-treated wt 
mouse (dark bar) and the L-carnitine-treated tg mouse (dark grey bar) at 16 weeks of age. 
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Figure 13. Polyclonal EM48 positivity 
of cortical sections (A,C) and striatal 
sections (B,D) of 16-week-old control and 
L-carnitine-treated transgenic mouse 
brains. Scale bar = 25 mm. Diagram 
shows the mean number of EM48-IR cells 
in the pyriform cortex and in the striatum 
of L-carnitine-treated (dark bar) and 
control (light bar) transgenic mice.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In all, we showed that L-carnitine treatment in higher dose significantly increased 
survival and ameliorated the motor symptoms in HD transgenic mice, moreover it was found 
to be neuroprotective for striatal neurons. 
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V. Discussion 
In this PhD work we showed additional evidence of the involvement of the molecular 
motor dynein and mitochondrial dysfunction in the pathogenesis of neurodegenerative 
diseases. 
First, we demonstrated the in vivo requirement of cytoplasmic dynein in the 
function of the striatum. Cramping mice display early onset motor and behavioural 
abnormalities such as abnormal gait, hind limb clasping, motor incoordination, muscle 
weakness and hyperactivity. A relatively mild proprioceptive neuropathy was proved 
previously in dynein mutant mice (Dupuis et al., 2009; Chen et al., 2007; Ilieva et al., 2008), 
but this does not explain the overall behavioural disturbances observed here, rather central 
involvement is suggested. The phenotype of Cra/+ mice resembles striatal pathology. 
Transgenic mice of HD also show abnormal gait and limb clasping when held by the tail, and 
at the early phase of the disease they have an increased spontaneous locomotor activity 
(Mangiarini et al., 1996; Schilling et al., 1999; Luesse et al., 2001; Bolivar et al., 2004). A 
similar phenotype is observed in PGC-1α -/- mice (Lin et al., 2004; Leone et al., 2005) and in 
transgenic mice lacking cortical BDNF or conditionally ablated for BDNF at adulthood 
(Baquet et al., 2004; Rauskolb et al., 2010). All of these transgenic animals present clear-cut 
lesion in the striatum. Besides, the genetic ablation of D1 dopamine receptor expressing cells 
within the striatum results also in a motor phenotype very similar to that observed in 
Cramping mice (Gantois et al., 2007). In addition others from our workgroup observed that 
dynein mutant mice exhibit HD-related peripheral phenotypes including increased adiposity 
and impaired brown adipose tissue thermogenesis (Eschbach et al., 2011), thus strengthening 
the analogy between HD animal models and dynein mutant mice. Our further histological, in 
vivo brain imaging findings verified the striatal involvement in Cramping mice. 
Interestingly, the behavioural phenotype of Cra/+ mice and striatal atrophy detected 
by MRI, appeared between 3 and 5 months of age, while astrocytosis, decreased gene 
expression of D1 receptors and decreased binding potential of D1, D2 receptors were 
detectable later, after 8 months of age. The fact that behavioural abnormalities forego marked 
histopathological and biochemical changes in the striatum is not without precedent. For 
instance, previous studies reported that motor dysfunction in huntingtin knock-in mice 
occurred long before any clear signs of striatal lesions (Menalled et al., 2002). Of note, 
conventional research of neurodegeneration focused on neuronal cell death related alterations 
as earlier the research possibilities were mainly limited to post mortem brain tissues from 
patients where cell death was obvious. The identification of neurodegeneration related genes 
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and the occurrence of transgenic animal models permitted to study early pathogenic events 
(Wong et al., 2002; Price et al., 2000). It turned out that significant abnormalities are 
detectable before any obvious signs of neuronal loss in most animal models. Moreover, 
further studies (behavioural, functional imaging, pathological, electrophysiological) in 
asymptomatic or early symptomatic patients with familial neurodegenerative diseases clearly 
demonstrated signs of neuronal dysfunction in the absence of overt neuronal cell death 
(Morfini et al., 2009). We did not detect decreased DARPP32 neuronal counts, showing that 
the striatal phenotype was not associated with cell death of MSNs. Our data however does not 
exclude the occurrence of a very slow and subtle process of striatal neurodegeneration that 
would be difficult to detect. Also, astrocytosis itself might be an astrocyte-autonomous event. 
Dynein expression and function in astrocytes has been poorly characterized and the 
elucidation of astrocytic dynein to the phenotype of dynein mutant mice will require the 
generation of conditional knock out mice. 
We found that gene expression of D1 receptor, as well as binding potential of [11C] 
SCH-23390, a D1 receptor selective radioligand, was decreased in Cra/+ striatum. Curiously, 
despite the binding potential of D2 receptor was decreased, its gene expression was 
unaffected. There are several potential explanations for this discrepancy. The binding 
potential calculated from PET analysis is a reflection of both the density of available receptor 
sides and the apparent ligand affinity (Laruelle, 2000). Since apparent ligand affinity is 
decreased by competition with the natural ligand, dopamine, an increase in striatal dopamine 
could in principle explain a decreased binding potential observed with PET. However, this 
explanation is unlikely in our case as [18F]Fallypride is a high affinity antagonist radioligand, 
and therefore less sensitive to changes in synaptic dopamine than agonist radioligands 
(Laruelle, 2000). Thus, the lower D2 binding potential observed in Cra/+ mice is most likely 
due to a reduction of D2 receptor binding sites rather than to increased striatal dopamine. 
Such a decrease might be explained by defects in the various trafficking events that modulate 
cell surface expression of D2 receptor (Xiao et al., 2009; Tirotta et al., 2008; Kim et al., 
2008). Indeed, given the involvement of dynein in a number of cellular trafficking events, it 
cannot be excluded that dynein mutation might directly impair D2 receptor trafficking. 
Other works also implicated dynein in diseases with striatal involvement, notably HD. 
The dynein/dynactin motor complex plays an important role in the delivery of 
autophagosome, in the process of autophagosome-lysosome fusion (Webb et al., 2004, 
Ravikumar et al., 2002). In neurons, autophagosome formation occurs at the axon tip, 
autophagosomes are transported retrogradely to perinuclear locations where lysosomes are 
    
37 
concentrated (Rubinsztein et al., 2005; Wong and Holzbaur 2014). Disrupted dynein function 
(even by inhibitors or genetic manipulations) results increased aggregate formation in cells, 
flies and mice, in connection with decreased autophagic clearance of aggregate-prone proteins 
e.g. mutant HTT (Ravikumar et al., 2005; Wiesner et al., 2014). Moreover, the toxicity of 
mutant HTT is enhanced by dynein dysfunction in neuronal precursor cell lines and the 
mutant HTT caused phenotype is aggravated in flies and mice by dynein mutation - detected 
when crossbreeding transgenic HD mice with Loa/+ dynein mutant mice (Ravikumar et al., 
2005). Huntingtin (HTT) and its associated protein HAP1 bind to dynein directly and 
indirectly, through dynactin subunit P150Glued (Li et al., 1995; Li et al., 1998). Mutant HTT 
disrupts these interactions and decreases dynein function (Caviston et al., 2007; Caviston and 
Holzbaur, 2009), although mutant HTT affects not only retrograde but also anterograde 
axonal transport (Morfini et al., 2009). On the other hand inhibition of dynein function in 
HeLa cells causes a significant redistribution of HTT to the cell periphery, suggesting that 
dynein is required for transport of HTT towards the cell center (Caviston et al., 2007). 
Moreover live-cell imaging studies proved that HTT and HAP1 colocalize with 
autophagosomes and control their dynamics via regulating the dynein and kinesin motors 
(Wong and Holzbaur, 2014). HTT/HAP1 complex enhances retrograde motility and promotes 
autophagosome transport towards the cell body for degradation. Further, in striatal cells from 
HD knock-in mice or mutant HTT expressing primary neurons disrupted autophagosome 
transport was observed causing defects in cargo degradation and ineffective clearance of 
dysfunctional mitochondria and mutant HTT (Wong and Holzbaur, 2014). 
Further to detect a mechanism which could be responsible for the striatal dysfunction 
we observed in Cramping mice we investigated abnormalities in striatal afferentation. The 
substantia nigra pars compacta dopaminergic neurons were however preserved when 
performing stereological assessments of tyrosine hydroxylase positive neurons (see Appendix 
I., Braunstein et al., 2010). We also examined whether deprivation or impaired response of 
brain-derived neurotrophic factor (BDNF), the major trophic factor for MSNs could be 
affected. But neither BDNF deprivation appeared to be a cause of dynein mutant striatal 
phenotype (see Appendix I., Braunstein et al., 2010). Indeed, we found that dynein mutant 
striatal neurons had dramatically impaired neuritic arborisation in cultured neurons while 
sparing survival of these cells (see Appendix I., Braunstein et al., 2010). 
In summary, our findings provide direct evidence of the involvement of axonal 
transport machinery, notably dynein in the maintenance of striatal function and may have 
major implications for our understanding of the pathogenesis of HD. 
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Besides dynein disruption we investigated the role of mitochondrial dysfunction in 
neurodegeneration. We showed that full length PGC-1α is absolutely required for 
compensatory mitochondrial proliferation occurring in Cramping mice, confirmed by 
the fact that its ablation strongly exacerbates metabolic and neurological phenotype in 
these mice. 
Increased number of mitochondria in muscle is a hallmark of human mitochondrial 
diseases although the underlying mechanisms are unclear. Mitochondrial proliferation is also 
observed in a subset of patients with neuropathies similar to DYNC1H1 mutations (Yu-Wai-
Man et al., 2010; Sitarz et al., 2012). Others from our workgroup previously described 
decreased mitochondrial respiration in white adipose tissue (WAT) and skeletal muscles 
along with increased mitochondrial area in muscle of Cramping mice (Eschbach et al., 2013). 
Furthermore, increased and not decreased mtDNA levels was found in tibialis anterior (TA) 
muscle, gastrocnemius muscle, WAT and striatum of Cramping mice (see Appendix II.,  
Róna-Vörös et al., 2013). This increased mitochondrial mass was not accompanied by large-
scale deletions of mtDNA suggesting that the mtDNA maintenance is functional. 
Interestingly, this compensatory response was not observed in cultured embryonic striatal 
neurons or fibroblasts, even in homozygous Cramping cells (see Appendix II., Róna-Vörös et 
al., 2013). Thus, mtDNA copy number is increased in vivo in Cramping mice as a possible 
compensatory response. The activation of PGC-1α, a transcriptional coactivator responsible 
for mitochondrial biogenesis, was hypothesized to underlie these observations. Overnight 
fasting followed by 6 hours of re-feeding further increased mtDNA levels in Cramping 
muscles accompanied by increased level of total PGC-1α mRNA (see Appendix II., Róna-
Vörös et al., 2013). This increase was due to FL- and NT-PGC-1α isoforms, the alternatively 
spliced IT-isoforms PGC-1α2 and 3 were unaffected. Moreover the expression of canonical 
targets of PGC-1α were examined for further support (see Appendix II., Róna-Vörös et al., 
2013). Altogether these data showed that mitochondrial proliferation in Cramping mice 
correlates with transcriptional induction of both FL- and NT-PGC-1α. 
The widely documented function of FL-PGC-1α in mitochondrial physiology suggested 
focusing on this specific isoform as a potential key player in mitochondrial proliferation. We 
showed definitive evidence of FL-PGC-1α involvement by a complete reversal of several 
indicators of mitochondrial proliferation upon FL-PGC-1α ablation in Cramping mice. In the 
FL-PGC-1α -/- mice we used for our experiments, NT isoforms are functionally preserved, as 
shown previously by others (Chang et al., 2012) and by our workgroup in skeletal muscle. It 
follows that NT isoforms are not able to substitute for FL isoforms and induce mitochondrial 
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proliferation. This function present in FL-PGC-1α but not in NT isoforms might be due to 
differences in nuclear import. Indeed, NT isoforms accumulate in the cytoplasm, while FL 
isoforms are exclusively nuclear (Chang et al., 2010; Shen et al., 2012). It is thus possible that 
a constitutive nuclear presence is necessary for PGC-1α to trigger mitochondrial proliferation. 
Alternatively, the domains of FL-PGC-1α not present in NT-isoforms include many 
interaction sites with important transcription factors such as PPARs, FoxO1 or MEFC2 
(Zhang et al., 2009). Each of these factors might be critical in this mitochondrial proliferation 
function. It is also possible that post-transcriptional mechanisms required for triggering 
mitochondrial proliferation target domains exclusively present in FL-isoforms. In all, FL-
PGC-1α is necessary for mitochondrial proliferation, while NT-PGC-1α is not sufficient. NT-
PGC-1α, although not sufficient, could however be necessary for mitochondrial proliferation, 
and answering this question will require specific knock-out mice that are currently not 
available. 
Our results support PGC-1α activation and increased mitochondrial biogenesis 
underlying the increased mitochondrial mass observed in Cramping mice, however it is not 
excluded that decreased mitochondrial autophagy caused by the dynein mutation may also 
partially contribute to this phenotype. The above discussed growing evidences for the role of 
dynein in autophagy stand for this potential (Wong and Holzbaur, 2014). Further 
investigations are needed to answer this question carefully. 
FL-PGC-1α ablation, and subsequent loss of mitochondrial proliferation, strongly 
exacerbated the previously observed abnormalities of Cramping mice, both metabolic (muscle 
mitochondrial function) and neurological (grip strength, rotarod, tremors). New defects 
appeared in Cra/FLα -/- mice that were absent in single transgenic mice, in particular a 
pronounced kyphosis, profound hair and weight loss and inability to rear. The respective 
mechanisms underlying these different phenotypes remain unknown, especially whether they 
are the consequences of worsened mitochondrial dysfunction. 
We observed gender differences in body temperature regulation. Others from our 
workgroup previously observed decreased rectal temperature in aged male Cramping mice 
(Eschbach et al., 2011). This difference in body temperature is also observed in the current 
study when considering only aged males, although the difference is smaller than reported by 
Eschbach et al., 2011. There are several explanations for this discrepancy, such as the use of 
different detection methods (subcutaneous temperature chips in this study, rectal probe in the 
other), also the different genetic background of the mice due to cross breedings. Our present 
data show, that the ablation of FL-PGC-1α was on its own sufficient to lead to hypothermia in 
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male mice, while addition of a Cramping allele was necessary to lead to hypothermia in 
females. This reinforces the observation that dynein and FL-PGC-1α are both important for 
thermogenesis in mice (Leone et al., 2005; Eschbach et al., 2011; Puigserver et al., 1998). It 
also illustrates the higher basal thermogenic capacity in female rodents as compared with 
males (Rodriguez-Cuenca et al., 2002) as well as the gender-dependent effects of FL-PGC-1α 
which was previously observed in another mouse model of neurodegeneration (Eschbach et 
al., 2013). The underlying mechanisms for impaired thermogenesis will require further 
investigation, in particular to determine whether this is due to impaired mitochondrial 
function and/or impaired beta-adrenergic signalling. 
Our cross breeding results indicate that the mitochondrial proliferation elicited by FL-
PGC-1α increased activity is able to mitigate the phenotype of Cramping mice. This is in line 
with other experiments that showed that transgenic overexpression of FL-PGC-1α is able to 
attenuate symptoms of mitochondrial diseases in a tissue specific manner (Wenz et al., 2008, 
2009; Dillon et al., 2012; Srivastava et al., 2009). Moreover PGC-1α overexpression 
selectively in skeletal muscle of transgenic mouse model of ALS improved muscle endurance 
and locomotor activity at symptomatic stages of the disease (Da Cruz et al., 2012). Lentiviral-
mediated expression of PGC-1α in the striatum of R6/2 transgenic mouse model of HD was 
neuroprotective preventing neuronal atrophy in these mice (Cui et al., 2006). On the other 
hand crossbreeding PGC-1α knock-out mice with HD knock-in mice worsened significantly 
the behavioural and neuropathological abnormalities, which deleterious effect was even more 
profound after 3-NP administration (Cui et al., 2006). 
Our data highlight the role of PGC-1α activation in diseases with mitochondrial 
dysfunction and might provide potential therapeutic targets. Such an approach has already 
been tested with bezafibrate, a pan-PPAR agonist able to increase PGC-1α activity (Wenz et 
al., 2008), but the mechanisms involved have recently been challenged (Viscomi et al., 2011; 
Yatsuga and Suomalainen, 2012). Besides, interventional studies with pioglitazone and 
rosiglitazone, both able to induce PGC-1α expression and activate the PPAR pathway 
(Hondares et al., 2006) were found to be beneficial in rodent models of ALS (Kiaei et al., 
2004; Schutz et al., 2005) or PD (Breidert et al., 2002; Dehmer et al., 2004). Interestingly, 
microtubule inhibitors were found to induce PGC-1α expression in primary satellite skeletal 
muscle cells (Arany et al., 2008). The elucidation of the mechanisms underlying re-feeding 
induced increase in mtDNA might provide alternative targets. This pathway might also be of 
high interest for other diseases in which PGC-1α modulates the disease process. This is 
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especially the case for HD, where specific PPARGC1A gene variants are associated with 
changes in the clinical course (Soyal et al., 2012; Weydt et al., 2014, 2009). 
In all, we demonstrated here that the full-length isoform of PGC-1α is required for 
disease induced mitochondrial proliferation and cannot be substituted by its N-terminally 
truncated isoforms. We also showed the protective potential of FL-PGC-1α against 
mitochondrial dysfunction, which has major implications in neurodegeneration and might 
provide potential therapeutic targets. 
An indirect way to support mitochondrial involvement in neurodegeneration is via 
therapeutic interventions with drugs affecting mitochondrial functions. We found that in 
higher doses L-carnitine (LC) produced significant improvement in survival and 
locomotor activity (including total distance moved, immobility time and velocity) in the 
N171/82Q transgenic mouse model of HD. Though in an earlier human study, no significant 
changes were observed upon low dose LC on the abnormal involuntary movement scale, the 
mini-mental status, the reaction time and verbal fluency (Goety et al., 1990). During the one 
week (45 mg/kg/day) treatment period there were no serious side effects detected (Goety et 
al., 1990). In our experiment, the improvement in survival of 14,91% is nearly equivalent to 
the effects of other compounds with antioxidant properties, such as BN82451, remacemide 
and coenzyme Q10, although slightly less than the effects of creatine and cysteamine 
(Dedeoglu et al., 2002; Ferrante et al., 2002; Klivényi et al., 2003, Schilling et al., 2001).  
The neuropathology of HD involves a selective neuronal loss, which occurs most 
markedly in the striatum and in deeper layers of the cerebral cortex (Ferrante et al., 1997). In 
the striatum, the loss of MSNs is most prevalent (Walker, 2007). The N171-82Q transgenic 
mouse model of HD resembles this pathological changes, others demonstrated 25% neuronal 
cell loss in the striatum of N171-82Q mice at 16 weeks of age and a 20% decrease in striatal 
cell volume (McBride et al., 2006). We also reproduced this striatal neuronal loss in vehicle-
treated transgenic HD mice compared with wild-type animals. This decline was significantly 
reverted under LC treatment.   
The N-terminal fragments of mutant HTT, which are expressed ubiquitously in both the 
nervous system and the peripheral tissues (Ferrante et al., 1997; Landwehrmeyer et al., 1995; 
Sharp et al., 1995; Strong et al., 1993) accumulate in the nucleus of affected neurons and form 
intranuclear aggregates (DiFiglia et al., 1997; Gutekunst et al., 1999). These huntingtin 
aggregates usually cause transcriptional dysregulation (Cha, 2000; Sugars and Rubinsztein, 
2003), which leads to subsequent altered signal cascades among others involved in oxidative 
stress (Beal and Ferrante 2004). In our results there were significant decreases in EM48 
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immunoreactivity in the pyriform cortex of LC-treated N171-82Q mice and a slight decrease 
in the striatum relative to the vehicle-treated group. 
LC and its acetyl ester, acetyl-LC (ALC) were found to be neuroprotective in different 
animal models of neuronal dysfunction / neurodegeneration, such as in spinal cord injury 
(Karalija et al., 2012; 2014), mitochondrial toxin models induced by MPTP, 3-NP, rotenone 
(Virmani et al., 2005; Silva-Adaya et al., 2008; Zaitone et al., 2012), and methamphetamine 
induced neurotoxicity (Virmani et al., 2002). ALC showed neuroprotective properties in rats 
exposed to global hypoxia via inducing PGC-1α and nuclear respiratory factor-1 mediated 
mitochondrial biogenesis (Hota et al., 2012). Recent data obtained from patients with 
inherited neurometabolic diseases confirmed the involvement of L-carnitine in the 
pathogenesis and supposed LC supplementation as beneficial (Ribas et al., 2014). Several 
studies were performed in AD and dementia, and however preclinical studies and earlier 
clinical studies suggested a protective effect of ALC treatment, a Cochrane meta-analysis 
revealed that there is no evidence of benefit for ALC treatment in dementia and AD (Hudson 
and Tabet, 2003). Though recently published data of a phase II randomized clinical trial with 
combinatorial nutritional supplementation (also including ALC) is promising, confirming a 
significant improvement in dementia rating scale (Remington et al., 2015). 
The importance of reactive oxygen species (ROS) and free radicals has an increased 
attention in the last decade, since these molecules are aggravating factors in cellular injury 
and aging processes (Halliwell, 2001; Calabrese et al., 2012). A substantial body of evidence 
suggests a role of excitotoxicity and oxidative damage in the HD pathogenesis (Johri et al., 
2013; Chaturvedi and Beal, 2013; Gil-Mohapel et al., 2014). It has been demonstrated that the 
expression of mutant HTT in neuronal and non-neuronal cells causes increased ROS, which 
contributes to cell death (Wyttenbach et al., 2002; St-Pierre et al., 2006). They raise the 
possibility that agents, which have antioxidative activity, may be useful as therapies to slow 
the progression of neurodegeneration in HD. 
We demonstrated that L-carnitine administration to N171-82Q transgenic mice extends 
the survival, ameliorates the motor performance, preserves striatal neuron count and decreases 
the number of intranuclear HTT aggregates, these parameters being important in the 
pathomechanism of HD. We suggest that L-carnitine may develop its effect through 
decreasing the oxidative damage. While the exact mechanism responsible for the beneficial 
effects of LC in N171-82Q mice is uncertain, our data suggest that L-carnitine is 
neuroprotective and may possibly be beneficial in the treatment of HD. 
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VI. Conclusions 
We investigated the role of retrograde axonal transport, notably the molecular motor 
dynein and mitochondrial dysfunction in neurodegeneration using different mouse models. 
First, we showed that cytoplasmic dynein is required for the maintenance of striatal function. 
We demonstrated that the Cramping mutation in the dynein heavy chain gene caused a 
characteristic behavioural phenotype with striatal atrophy and dysfunction in mice confirmed 
by multimodal approaches. This finding may have major implications for our understanding 
of the pathogenesis of striatal diseases, notably HD. Second, we proved that the overall 
mitochondrial proliferation observed in Cramping mice is FL-PGC-1α dependent. We 
showed that genetic ablation of FL-PGC-1α significantly worsened the overall, neurological 
and mitochondrial phenotype of these mice. It suggests that FL-PGC-1α is required for the 
compensatory maintenance of mitochondrial function in Cramping mice. This observation 
helps to understand better the underlying mechanisms in mitochondrial dysfunction related to 
disease. Third, we showed that L-carnitine, a nutrient with antioxidant properties also 
enhancing mitochondrial function, ameliorates the motor symptoms and increases survival in 
a HD transgenic mouse model. Moreover it was found to be neuroprotective for striatal 
neurons, the neuronal population markedly affected in HD. Thus, L-carnitine may be a 
promising compound in the therapy of Huntington's disease. 
In all, our findings highlight the role of the molecular motor dynein and mitochondrial 
dysfunction in neurodegeneration, notably in Huntington's disease. These data contribute to 
better understanding of the pathomechanism of neurodegenerative diseases and offer potential 
therapeutic ways. 
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